Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Infinigence | Xuhui | Series C | $343.7M | 2026-10-12 |
| Shengshu Technology | Beijing | Series B | $292.7M | 2026-04-10 |
| Insta360 | Shenzhen | Series E | $20.0M | 2019-09-01 |
| Sanegene Bio | Woburn | Series B | $110.0M | 2025-12-08 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Axera | Beijing | Series C | $136.1M | 2025-04-09 |
| BreezeBio | Brisbane | Series B | $60.0M | 2026-02-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 154 Qiming Venture Partners portfolio companies have raised $7.6B in total.
- 21 of them closed their most recent round in the last 12 months, $1.6B combined.
- The largest of those rounds is Infinigence's $343.7M Series C, dated October 2026.
- GGV Capital is an investor in 12 of them, more than any other fund.
- Software is the most common sector, with 101 companies (66%).
- 20% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (33% of companies with a recorded size).
- 6 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 154| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Infinigence | Infinigence develops AI infrastructure and computing solutions for training and deploying AI models. | Artificial intelligence | Xuhui, China | Series C | $343.7M | 2026-10-12 | $587.5M | Qiming Venture Partners, Legend Capital | 51 to 100 | 2023 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang, China | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou, China | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | San Francisco, United States | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai, China | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| Shengshu Technology | Shengshu Technology develops artificial intelligence systems for generative video and multimodal content creation. | Artificial intelligence | Beijing, China | Series B | $292.7M | 2026-04-10 | $441.5M | Qiming Venture Partners, Baidu Ventures, Zhuoyuan Capital +1 | 101 to 250 | 2023 |
| CIX Technology | CIX Technology develops high-performance intelligent computing solutions. | Hardware | Shanghai, China | Series B | $144.7M | 2026-03-30 | $194.7M | Qiming Venture Partners, Shunwei Capital, Lenovo Capital and Incubator Group (LCIG) +2 | 11 to 50 | 2021 |
| CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian, China | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| Tingsheng Technology | Tingsheng Technology develops intracardiac ultrasound (ICE) products. | Health care | Nanjing, China | Series B | $13.9M | 2026-03-05 | $52.8M | Qiming Venture Partners, Taiyu Investment, Tao Capital +2 | 2017 | |
| Ruining Bio | Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection and wound repair. | Health care | Jiading, China | Series C | $14.6M | 2026-02-28 | $38.8M | Qiming Venture Partners, Taiyu Investment, Dingxin Capital +1 | 2018 | |
| BreezeBio | BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. | Artificial intelligence | Brisbane, United States | Series B | $60.0M | 2026-02-25 | $127.7M | Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 | 51 to 100 | 2016 |
| Chaitin Tech | Chaitin Tech provides technology-driven cybersecurity solutions. | Cybersecurity | Beijing, China | Series B | $71.9M | 2026-01-27 | $232.5M | Matrix Partners China, ZhenFund, Qiming Venture Partners +1 | 101 to 250 | 2014 |
| PRCXI Biotechnology | PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. | Biotech | Suzhou, China | Series A | $14.0M | 2025-12-31 | $55.0M | Qiming Venture Partners, SAIF Partners | 101 to 250 | 2014 |
| DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian, China | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| SonoSilicon | SonoSilicon researches medical-grade micro-on-chip ultrasound systems and chip design. | Health care | Hangzhou, China | Seed | $5.5M | 2025-12-11 | $5.5M | Qiming Venture Partners | 11 to 50 | 2023 |
| Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn, United States | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| Brise Pharma | Brise Pharma provides scientific research and technical services in the pharmaceutical field. | Biotech | Shanghai, China | Series A | $28.1M | 2025-11-11 | $228.3M | Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 | 11 to 50 | 2021 |
| Mech-Mind Robotics | Mech-Mind Robotics makes industrial 3D sensors and AI software for intelligent robots. | Artificial intelligence | Beijing, China | Series D | $69.9M | 2025-08-26 | $341.8M | Sequoia Capital, Intel Capital, Qiming Venture Partners | 501 to 1,000 | 2016 |
| Qianshou | Qianshou is a dating app that matches users with potential life partners through artificial matchmaking. | Artificial intelligence | Tianjin, China | Series B | $30.5M | 2025-06-12 | $30.5M | Qiming Venture Partners | 1 to 10 | 2019 |
| Axera | Axera develops artificial intelligence SoCs for computer applications as a semiconductor company. | Artificial intelligence | Beijing, China | Series C | $136.1M | 2025-04-09 | $262.1M | Qiming Venture Partners, Legend Star, Glory Ventures +1 | 251 to 500 | 2019 |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. | Artificial intelligence | Cambridge, United States | Series E | $123.0M | 2025-03-13 | $624.3M | Qiming Venture Partners, F-Prime, Warburg Pincus +1 | 101 to 250 | 2014 |
| Hope Medicine | Hope Medicine develops science-driven biopharmaceutical treatments in clinical development. | Health care | Nanjing, China | Series B | $18.5M | 2024-09-27 | $102.6M | Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners +2 | 1 to 10 | 2018 |
| Guangjing Energy | Guangjing Energy develops perovskite solar cell modules for industrialized mass production and sales. | Energy | Foshan, China | Series A | $17.8M | 2024-08-22 | Qiming Venture Partners, Sinovation Ventures, CICC | 11 to 50 | 2022 | |
| DST Car | DST Car is an energy vehicle rental service platform based in Shenzhen. | Commerce | Shenzhen, China | Series E | $100.0M | 2024-07-09 | Matrix Partners China, Qiming Venture Partners, CICC +1 | 501 to 1,000 | 2015 | |
| Alpha Biopharma | Alpha Biopharma is a clinical-stage biopharmaceutical company. | Biotech | Huangpu, China | Series B | $23.9M | 2024-06-22 | Qiming Venture Partners, TF Capital, LYZZ Capital | 51 to 100 | 2017 | |
| DK MedTech | DK MedTech manufactures vascular interventional medical device products. | Health care | Suzhou, China | Series E | $24.5M | 2024-06-21 | $36.2M | Qiming Venture Partners, Legend Capital, Oriza Seed Capital (Oriza Yuandian) +1 | 251 to 500 | 2015 |
| Yidao Biotechnology | Yidao Biotechnology researches and develops vaccines and biomedical products. | Biotech | Suzhou, China | Series D | $25.2M | 2024-05-09 | Qiming Venture Partners, Northern Light Venture Capital | 2017 | ||
| Mach Intelligent Driving | Mach Intelligent Driving provides driving solutions built on intelligent sensor function modules. | Artificial intelligence | Wuhu, China | Angel | $4.1M | 2024-04-24 | Qiming Venture Partners | 2022 |
Table 1. Qiming Venture Partners portfolio companies: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 154.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Infinigence | Infinigence develops AI infrastructure and computing solutions for training and deploying AI models. | Artificial intelligence | Xuhui, China | Series C | $343.7M | 2026-10-12 | $587.5M | Qiming Venture Partners, Legend Capital | 51 to 100 | 2023 |
| 2 | Shengshu Technology | Shengshu Technology develops artificial intelligence systems for generative video and multimodal content creation. | Artificial intelligence | Beijing, China | Series B | $292.7M | 2026-04-10 | $441.5M | Qiming Venture Partners, Baidu Ventures, Zhuoyuan Capital +1 | 101 to 250 | 2023 |
| 3 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 4 | CIX Technology | CIX Technology develops high-performance intelligent computing solutions. | Hardware | Shanghai, China | Series B | $144.7M | 2026-03-30 | $194.7M | Qiming Venture Partners, Shunwei Capital, Lenovo Capital and Incubator Group (LCIG) +2 | 11 to 50 | 2021 |
| 5 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 6 | DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian, China | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| 7 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn, United States | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 8 | Chaitin Tech | Chaitin Tech provides technology-driven cybersecurity solutions. | Cybersecurity | Beijing, China | Series B | $71.9M | 2026-01-27 | $232.5M | Matrix Partners China, ZhenFund, Qiming Venture Partners +1 | 101 to 250 | 2014 |
| 9 | BreezeBio | BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. | Artificial intelligence | Brisbane, United States | Series B | $60.0M | 2026-02-25 | $127.7M | Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 | 51 to 100 | 2016 |
| 10 | CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian, China | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
Table 2. Qiming Venture Partners portfolio companies: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | GGV Capital | Venture capital firm | Menlo Park, United States | 12 | 8% | ||
| 2 | Matrix Partners China | Venture capital firm | Beijing, China | 11 | 7% | 3 | Houmo.AI, Chaitin Tech, DP Technology |
| 3 | IDG Capital | Private equity firm | Beijing, China | 9 | 6% | ||
| 4 | Shunwei Capital | Venture capital firm | Beijing, China | 8 | 5% | 2 | LTZ Therapeutics, CIX Technology |
| 5 | ZhenFund | Entrepreneurship program | Beijing, China | 7 | 5% | 1 | Chaitin Tech |
| 6 | Source Code Capital | Venture capital firm | Chaoyang, China | 7 | 5% | 1 | DP Technology |
| 7 | CICC | Investment bank | Beijing, China | 7 | 5% | ||
| 8 | K2VC | Angel group | Beijing, China | 6 | 4% | 2 | LTZ Therapeutics, Sanegene Bio |
| 9 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 6 | 4% | 1 | Sanegene Bio |
| 10 | Legend Capital | Venture capital firm | Beijing, China | 5 | 3% | 2 | Infinigence, Chaitin Tech |
| 11 | Sequoia Capital | Venture capital firm | Menlo Park, United States | 4 | 3% | 1 | BreezeBio |
| 12 | DCM Ventures | Venture capital firm | Menlo Park, United States | 4 | 3% | ||
| 13 | Taiyu Investment | Venture capital firm | Beijing, China | 4 | 3% | 3 | Novamab, Tingsheng Technology, Ruining Bio |
| 14 | SAIF Partners | Private equity firm | Hong Kong | 4 | 3% | 1 | PRCXI Biotechnology |
| 15 | SIG China (SIG Asia Investments) | Private equity firm | Huangpu, China | 4 | 3% |
Table 3. Qiming Venture Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Software | 101 | 66% | $4.5B |
| Health care | 40 | 26% | $4.0B |
| Artificial intelligence | 36 | 23% | $3.7B |
| Hardware | 30 | 19% | $1.7B |
| Biotech | 24 | 16% | $3.1B |
| Fintech | 18 | 12% | $169.6M |
| Education | 9 | 6% | $3.1M |
| Commerce | 9 | 6% | |
| Cybersecurity | 6 | 4% | $232.5M |
| Energy | 3 | 2% | $54.2M |
Table 4. Qiming Venture Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Qiming Venture Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 123 | 80% |
| United States | 13 | 8% |
| Singapore | 7 | 5% |
| Hong Kong | 2 | 1% |
| Switzerland | 1 | 1% |
| India | 1 | 1% |
| Indonesia | 1 | 1% |
| Finland | 1 | 1% |
| Taiwan | 1 | 1% |
| Saint Kitts and Nevis | 1 | 1% |
| South Korea | 1 | 1% |
| Canada | 1 | 1% |
Table 6. Qiming Venture Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Qiming Venture Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 5% | |
| October 2026 | 1 | 5% | $343.7M |
| August 2026 | 1 | 5% | $120.0M |
| July 2026 | 1 | 5% | $29.0M |
| June 2026 | 1 | 5% | $14.7M |
| May 2026 | 2 | 10% | $203.0M |
| April 2026 | 2 | 10% | $336.6M |
| March 2026 | 4 | 19% | $203.6M |
| February 2026 | 3 | 14% | $74.6M |
| January 2026 | 1 | 5% | $71.9M |
| December 2025 | 4 | 19% | $243.4M |
Table 8. Qiming Venture Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 17 | 11% | $1.4B |
| 2025 | 14 | 9% | $713.1M |
| 2024 | 20 | 13% | $425.3M |
| 2023 | 17 | 11% | $269.5M |
| 2022 | 18 | 12% | $365.9M |
| 2021 | 14 | 9% | $1.3B |
Table 9. Qiming Venture Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 4% |
| 2020 to 2022 | 25 | 16% |
| 2015 to 2019 | 72 | 47% |
| 2010 to 2014 | 34 | 22% |
| Before 2010 | 17 | 11% |
Table 10. Qiming Venture Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 11 | 8% |
| 11 to 50 | 48 | 33% |
| 51 to 100 | 33 | 23% |
| 101 to 250 | 23 | 16% |
| 251 to 500 | 12 | 8% |
| 501 to 1,000 | 11 | 8% |
| 1,001 to 5,000 | 6 | 4% |
Table 11. Qiming Venture Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Qiming Venture Partners is recorded as one of its investors. On 16 November 2026 that is 154 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 154 rows: 29 have no round amount, 0 no city and 65 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Qiming Venture Partners portfolio companies are on the list?
- 154, in the file dated 16 November 2026. 21 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 154 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.